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History 
The first case of malignant hyperthermia (MH) that can be identified dates back to the 1960s when a 
patient with a known familial history of anesthesia complications demonstrated tachycardia, 
increased body temperature and hypotension following induction of anesthesia.  After this incident, 
clinicians described MH as an increased metabolic state that has a range of signs associated with 
induction of inhaled anesthetics (Seifert, Wahr, Pace, Cochrane, & Bagnola, 2014). 
Causes 
MH is a serious, life-threatening reaction that occurs after being exposed to certain inhaled and local 
anesthetics.   Some of the inhaled volatile anesthetic agents that can trigger MH include halothane, 
sevoflurane, desflurane and isoflurane (Genetics Home Reference, 2015).  MH is also known to be 
induced by succinylcholine, a depolarizing muscle relaxant and neuromuscular blocker that is used to 
protect the airway of those undergoing surgical procedures and can sometimes preserve the 
respiratory function during disease states.  The prevalence of persons that have experienced MH is 
said to be one in 5,000 to 50,000 individuals, but could be higher since not all is exposed to 
anesthesia (Rosenberg, Sambuughin, Riazi, & Dirksen, 2003).  Ama, T., Bounmythavong, S., Blaze, 
J., Weismann, M., Marienau, M., & Nicholson, W (2010) state that the prevelance in children can 
be as high as one in 15,000.  Emotional stress, trauma, or extreme heat stressors such as vigorous 
exercising and high temperatures can also trigger MH (Seifert, Wahr, Pace, Cochrane, & Bagnola, 
2014). 
Pathophysiology 
Malignant hyperthermia reactions are associated with over eighty genetic defects (Mitchell-Brown, 2012) with the gene RYR1 on chromosome 19 being the most prevalent.  The RYR1 is a ryanodine 
receptor that mediates calcium release from the sarcoplasmic reticulum, which is essential for muscle contraction.  Normal cell energy production and muscle contraction is mediated by calcium, 
which is an essential ion (Twine, 2014).  In MH, the release of calcium supersedes the reuptake of calcium resulting in the inability of muscle contraction termination (Ama, Bounmythavong, Blaze, 
Weismann, Marienau & Nicholson, 2010).  “The excessive calcium leads to sustained muscle contraction and rigidity, increasing metabolism and generating heat.  Eventually the overworked cells are 
depleted of oxygen and adenosine triphosphate (ATP), their energy source” (Mitchell-Brown, 2012).   MH is an autosomal dominant inherited disorder, meaning a child or sibling of a susceptible 
patient has a 50% chance of inheriting a defective gene (Mitchell-Brown, 2012). 
Signs and Symptoms 
Top left: Figure 1.  Representing excitation-contraction mechanism of muscles.  The action potential is initiated along the sacrolemmal membrane into the transverse 
tubule, where the dihdropyridine receptors (DHP receptor) senses the action potential voltage change and opens up.  This activates the ryanodine receptors, which 
release calcium from the sarcoplasmic reticulum (SR).  In malignant hyperthermia, an uncontrolled release of calcium from the SR overwhelms the compensatory 
mechanisms within the skeletal muscle cell.  This leads to increased muscle contraction and metabolic stimulation follows. Reprinted from Malignant Hyperthermia. O. 
Brandschapp & T. Girard, 2012, Swiss Medical Weekly, Volume (142): w13652. Copyright 2012 by Swiss Medical Weekly. Reprinted with permission. 
doi:10.4414/smw.2012.13652 
Top Right: Figure 2. Representing dominant inheritance with malignant hyperthermia.  Adapted from Recessive and Dominant Inheritance, n.d., Retrieved July 27, 2015, from 
http://www.accessexcellence.org/RC/VL/GG/recessive.php. Copyright 1999-2009 Access Excellence @ the National Health Museum. Adapted with permission. 
During a MH reaction, a person develops life-threatening skeletal muscle break down (increased 
metabolism) by elevated intracellular calcium that is rapidly released by the sarcoplasmic reticulum 
(SR) (Ama, Bounmythavong, Blaze, Weismann, Marienau, & Nicholson, 2010).   Rosenberg, 
Sambuughin, Riazi, and Dirksen (2013) state that “signs and symptoms could include acidosis, 
hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis 
with increase in serum creatine kinase concentration, hyperkalemia with risk of heart arrhythmias or 
even arrest, and myoglobinuria with a risk for renal failure.”  Early signs of MH are tachycardia and 
hypercapnia and are usually noticed first in the operating room.  The hallmark sign of malignant 
hyperthermia is increased body temperature, which can exceed 43.3 degrees Celsius, or 109.9 
degrees Fahrenheit.  This reaction is delayed in part due to hypothermia induced by the surgical 
room environment and anesthetics.  Cardiac arrest, kidney and liver failure, abnormal blood 
coagulation, internal hemorrhage, neurologic injury, cardiovascular collapse occur in those 
untreated MH reactions (Seifert, Wahr, Pace, Cochrane, & Bagnola, 2014).  The classic triad of late 
MH can lead to end-organ damage.  The triad includes muscle rigidity, usually noticed in the 
masseter muscles, hyperthermia and metabolic acidosis (Musselman & Saely, 2013). 
Treatment 
Once MH is suspected, it is extremely important to take prompt action to “discontinue the 
inhaled agent, hyperventilating the patient with 100% oxygen, administering intravenous 
dantrolene, cool the patient and treat the symptoms” (Ama, Bounmythavong, Blaze, 
Weismann, Marienau, & Nicholson, 2010) .  Without prompt treatment of dantrolene 
sodium, mortality is extremely high in persons with MH (Malignant Hyperthermia 
Association of the United States, 2015).  It is estimated that dantrolene can reduce the 
mortality rate of MH reactions from 40% to 1.4% (Denholm & Spruce, 2015).  Researchers 
estimate that 44 MH events occur every year in acute surgery centers and 33 lives were 
saved when using dantrolene sodium rather than only supportive measures (Aderibigbe, 
Lang, Rosenberg, Chen & Li, 2014).  Dantrolene decreases the release of calcium from the 
SR, which restores balance between the release and reuptake of calcium (Ama, 
Bounmythavong, Blaze, Weismann, Marienau, & Nicholson, 2010).  
Although the only chemical treatment for MH is dantrolene, it is important to be familiar 
with the potential side effects of this drug.  Side effects include muscle weakness, dizziness, 
dysarthia, drowsiness, and pulmonary edema.  Calcium channel blockers should be avoided 
with administration of dantrolene; this combination can lead to hyperkalemia and 
myocardial depression (Twine, 2014). 
Testing 
The most common diagnostic test for MH susceptibility is the caffeine halothane contracture 
test (CHCT).  This test requires a muscle biopsy and measure the contracture in response to 
halothane and caffeine.  Most people at risk and at increased susceptibility for MH will be 
identified with this test due to its high sensitivity.  Unfortunately, this test provides risk 
associated to biopsy sampling, invasiveness, expense and limited biopsy centers.  Genetic 
testing is also available in the United States for persons with a positive caffeine halothane 
contracture result.  Mitchell-Brown (2012) states that “the CHCT is performed only in 
specialized centers, thirty centers worldwide and only six in North America.  Because the 
CHCT test must be performed on a fresh muscle specimen, the patient must travel to one of 
these centers for testing.”  This genetic test screens for the 17 most common RYR1 
mutations, but also has its limitations.  Only 25% of the persons at risk for MH are detected 
because of the multitude of mutations associated with MH (Ama, Bounmythavong, Blaze, 
Weismann, Marienau, & Nicholson, 2010). 
The amount of procedures in the US alone top over 50 million, with many of them being done with 
local anesthesia (CDC, 2015).  With such a high number of cases in the continental United States, it 
is important to be aware of possible life-threatening side effects of anesthesia, such as MH.  
Professional health care workers, such as anesthesiologists, nurse anesthetists, critical care physicians, 
perioperative personal and registered nurses are the first line responders to recognizing the signs and 
symptoms of MH as well as prompt and proper treatment. 
It is extremely important to obtain a thorough anesthetic history before providing anesthesia for 
possible suspicions of MH reactions.  Once the person is identified as being at an increased risk, 
avoidance of the triggering agents is key.  It is not recommended or necessary to pretreat these 
patients with dantrolene, but having it available is crucial (Ama, Bounmythavong, Blaze, Weismann, 
Marienau, & Nicholson, 2010).   
Mortality has decreased 80% from the 1980s to less than 5% today (Ama, Bounmythavong, Blaze, 
Weismann, Marienau, & Nicholson, 2010).  Research has proven that stocking dantrolene and 
providing adequate education of MH and how to recognize and treat this condition has prevented 
mortality.  Nurses who care for patients during or after surgery must be knowledgeable of MH and 
since susceptibility to this reaction is inherited, nurses must educate patients and their families about 
the risk involved (Mitchell-Brown, 2012). 
Nursing Implications 
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